Hosted on MSN6mon
Pfizer to withdraw sickle cell treatment OXBRYTA from market
Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from worldwide markets. The company is also discontinuing all ...
Hosted on MSN6mon
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
The pharmaceutical giant last week announced it would voluntarily withdraw its sickle cell disease therapy, Oxbryta, from worldwide markets — to the surprise of doctors, patients and investors.
pharmaphorum1d
Pfizer pulls sickle cell med Oxbryta off market after deaths
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...
pharmaphorum6d
Price cut unlocks NHS use of sickle cell drug Oxbryta
It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...
Investing1mon
Global Blood Therapeutics Inc (GBT)
The company offers Oxbryta tablets, an oral once-daily therapy for SCD. It also evaluates pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and ...